BR0316324A - Polipeptìdeos e conjugados de interferon-alfa - Google Patents

Polipeptìdeos e conjugados de interferon-alfa

Info

Publication number
BR0316324A
BR0316324A BR0316324-5A BR0316324A BR0316324A BR 0316324 A BR0316324 A BR 0316324A BR 0316324 A BR0316324 A BR 0316324A BR 0316324 A BR0316324 A BR 0316324A
Authority
BR
Brazil
Prior art keywords
conjugates
polypeptides
interferon
nucleic acids
alpha polypeptides
Prior art date
Application number
BR0316324-5A
Other languages
English (en)
Inventor
Philip A Patten
Sridhar Govindarajan
Sridhar Viswanathan
Torben Lauesgaard Nissen
Original Assignee
Maxygen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Maxygen Inc filed Critical Maxygen Inc
Publication of BR0316324A publication Critical patent/BR0316324A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"POLIPEPTìDEOS E CONJUGADOS DE INTERFERON-ALFA". A presente invenção fornece polipeptídeos e conjugados de interferon-alfa e ácidos nucleicos que codificam os polipeptídeos. A invenção também inclui composições que compreendem esses polipeptídeos, conjugados e ácidos nucleicos; células contendo ou expressando os polipeptídeos, conjugados e ácidos nucleicos; métodos de fabricação dos polipeptídeos, conjugados e ácidos nucleicos; e métodos de uso dos polipeptídeos, conjugados e ácidos nucleicos.
BR0316324-5A 2002-11-18 2003-11-17 Polipeptìdeos e conjugados de interferon-alfa BR0316324A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42761202P 2002-11-18 2002-11-18
US50256003P 2003-09-12 2003-09-12
PCT/US2003/036682 WO2004046365A2 (en) 2002-11-18 2003-11-17 Interferon-alpha polypeptides and conjugates

Publications (1)

Publication Number Publication Date
BR0316324A true BR0316324A (pt) 2005-09-27

Family

ID=32329174

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0316324-5A BR0316324A (pt) 2002-11-18 2003-11-17 Polipeptìdeos e conjugados de interferon-alfa

Country Status (13)

Country Link
US (1) US20040219131A1 (pt)
EP (1) EP1565205A4 (pt)
JP (1) JP2006506097A (pt)
KR (1) KR20050086498A (pt)
AU (1) AU2003297285A1 (pt)
BR (1) BR0316324A (pt)
CA (1) CA2504267A1 (pt)
IL (1) IL168049A0 (pt)
MX (1) MXPA05005263A (pt)
NO (1) NO20052363L (pt)
NZ (1) NZ540043A (pt)
RU (1) RU2005118998A (pt)
WO (1) WO2004046365A2 (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7435562B2 (en) 2000-07-21 2008-10-14 Modular Genetics, Inc. Modular vector systems
US7959910B2 (en) 2000-07-31 2011-06-14 Biolex Therapeutics, Inc. C-terminally truncated interferon alpha variants
CA2498319A1 (en) * 2002-09-09 2004-03-18 Nautilus Biotech Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
BR0317742A (pt) 2002-12-26 2005-11-22 Mountain View Pharmaceuticals Conjugados poliméricos de interferon-beta com potência biológica aumentada
WO2004060300A2 (en) 2002-12-26 2004-07-22 Mountain View Pharmaceuticals, Inc. Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity
WO2004076474A2 (en) * 2003-02-26 2004-09-10 Intermune, Inc. Polyethylene glycol modified interferon compositions and methods of use thereof
WO2005070973A2 (en) * 2004-01-21 2005-08-04 Nektar Therapeutics Al, Corporation Method of preparing propionic acid-terminated polymers
JP2008507298A (ja) 2004-05-19 2008-03-13 マキシジェン， インコーポレイテッド インターフェロンαポリペプチドおよび結合体
CA2572751A1 (en) * 2004-06-30 2006-01-12 Egen Corporation Pegylated interferon alpha-1b
US20060024272A1 (en) 2004-07-29 2006-02-02 Large Scale Biology Corporation C-terminally truncated interferon
CA2590245A1 (en) 2004-11-11 2006-05-18 Modular Genetics, Inc. Ladder assembly and system for generating diversity
US9931413B2 (en) * 2005-04-06 2018-04-03 Ibc Pharmaceuticals, Inc. Tetrameric cytokines with improved biological activity
ES2772674T3 (es) * 2005-05-12 2020-07-08 Zymogenetics Inc Composiciones y métodos para modular respuestas inmunitarias
KR20080019619A (ko) 2005-05-18 2008-03-04 맥시겐, 인크. 개량된 인터페론-알파 폴리펩티드
KR101449587B1 (ko) * 2006-09-14 2014-10-10 메드제닉스 메디칼 이스라엘 리미티드 장기 지속형 약물 제형
US8454948B2 (en) 2006-09-14 2013-06-04 Medgenics Medical Israel Ltd. Long lasting drug formulations
CN1970572A (zh) * 2006-12-21 2007-05-30 北京三元基因工程有限公司 干扰素α突变体及其聚乙二醇衍生物
WO2008124086A2 (en) * 2007-04-05 2008-10-16 President And Fellows Of Harvard College Chimeric activators: quantitatively designed protein therapeutics and uses thereof
US7625555B2 (en) 2007-06-18 2009-12-01 Novagen Holding Corporation Recombinant human interferon-like proteins
JP2013532152A (ja) 2010-06-15 2013-08-15 メドジェニクス・メディカル・イスラエル・リミテッド 長期持続性の医薬製剤
US20130225789A1 (en) * 2012-02-29 2013-08-29 Yi Sun Polyethylene Glycol Having Hetero Multiple Functional Groups
AU2022328512A1 (en) * 2021-08-18 2024-03-28 Remd Biotherapeutics, Inc. Novel interferon variants and bifunctional fusion molecules thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6610830B1 (en) * 1980-07-01 2003-08-26 Hoffman-La Roche Inc. Microbial production of mature human leukocyte interferons
US4414150A (en) * 1980-11-10 1983-11-08 Genentech, Inc. Hybrid human leukocyte interferons
US4801685A (en) * 1981-08-14 1989-01-31 Hoffmann-La Roche Inc. Microbial production of mature human leukocyte interferon K and L
US4678751A (en) * 1981-09-25 1987-07-07 Genentech, Inc. Hybrid human leukocyte interferons
IE54592B1 (en) * 1982-03-08 1989-12-06 Genentech Inc Anumal interferons, processes involved in their production, compositions containing them, dna sequences coding therefor and espression vehicles containing such sequences and cells transformed thereby
US6936694B1 (en) * 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
US4885166A (en) * 1985-06-11 1989-12-05 Ciba-Geigy Corporation Hybrid interferons
US5574138A (en) * 1993-03-08 1996-11-12 Immunex Corporation Epithelium-derived T-cell factor
US6335160B1 (en) * 1995-02-17 2002-01-01 Maxygen, Inc. Methods and compositions for polypeptide engineering
TW517067B (en) * 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
DE60035871T2 (de) * 1999-05-19 2008-06-05 Merck Patent Gmbh Expression und export von interferon-alpha proteinen als fc fusionsproteine
MXPA02003492A (es) * 1999-10-07 2002-08-20 Maxygen Inc Homologos de interferon-alfa.
US20020025304A1 (en) * 2000-06-16 2002-02-28 Croze Edward M. Novel interferon for the treatment of multiple sclerosis
WO2002044197A2 (en) * 2000-12-01 2002-06-06 Fish Eleanor N Cytokine receptor binding peptides
RU2005118752A (ru) * 2002-11-15 2006-02-10 Ф.Хоффманн-Ля Рош Аг (Ch) Позиционные изомеры пэгилированного интерферона l-2а (конъюгата пэг-ifn-l-2а)

Also Published As

Publication number Publication date
EP1565205A2 (en) 2005-08-24
MXPA05005263A (es) 2005-07-25
JP2006506097A (ja) 2006-02-23
WO2004046365A2 (en) 2004-06-03
US20040219131A1 (en) 2004-11-04
KR20050086498A (ko) 2005-08-30
WO2004046365A3 (en) 2004-09-02
CA2504267A1 (en) 2004-06-03
NO20052363L (no) 2005-08-08
NZ540043A (en) 2007-11-30
AU2003297285A1 (en) 2004-06-15
RU2005118998A (ru) 2006-01-27
IL168049A0 (en) 2009-02-11
NO20052363D0 (no) 2005-05-12
EP1565205A4 (en) 2006-07-05

Similar Documents

Publication Publication Date Title
BR0316324A (pt) Polipeptìdeos e conjugados de interferon-alfa
ID30181A (id) Asam antranilat- dan asam tioantranilat-n-aril amida
BRPI0412845A (pt) herpes-vìrus, uso de um vìrus, composição farmacêutica, e, método de tratamento de um tumor em um indivìduo em necessidade do mesmo
NO20010013L (no) Svovelsubstituerte sulfonylaminokarboksylsyre N-arylamider, deres fremstilling og anvendelse samt farmasöytiske preparater inneholdende forbindelsene
TW200611910A (en) Interferon-alpha polypeptides and conjugates
DE69841285D1 (de) Bipolares Elektrodeninstrument
DE69811283T2 (de) Flüssige, härtbare Harzzusammensetzung
WO2006083276A3 (en) Interferon-alpha polypeptides and conjugates
DE69739738D1 (de) Epoxy-Polysiloxan-Polymer-Zusammensetzung
DK0975693T3 (da) Flydende hærdbar harpikssammensætning
DE60010098D1 (de) 28-epirapaloge
DK1047740T3 (da) Hærdelige harpikssammensætninger
TR200100056T2 (tr) Nörotrofik faktörler
DE69014944T2 (de) Härtbare Siloxanzusammensetzungen.
DE69822473D1 (de) Lipid-polyamid-konjugate und zusammensetzungen zur verabreichung von nucleinsäuremolekülen
DE69606414D1 (de) In Gegenwart von Wasser oder Luftfeuchtigkeit härtbare Siliconzusammensetzungen
DE69925820D1 (de) Zubereitungen zur stabilisierung von peg-interferon alpha konjugaten
DE69811794T2 (de) Härtbare Gummizusammensetzung
SE9602822D0 (sv) New receptor
DE59811071D1 (de) Präparation umfassend Thiolgruppen-haltige Proteine
BR9802803A (pt) ação e composições farmacêuticas contendo os mesmos.
BR0314139A (pt) Derivados de 1,4-pirazina substituìdos
DK0939769T3 (da) Vertebrat-Smoothened-proteiner
BR9915093B1 (pt) composição polimérica modificada com borracha melhorada.
ID27133A (id) Derivat-derivat asam sulfonilaminofin dan fosfonat

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]